LETTERS TO THE EDITOR. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-? antibody infliximab: report of three cases-Reference-Cited by-同舟云学术

LETTERS TO THE EDITOR. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-? antibody infliximab: report of three cases

Published:2007-02-06 Issue:0 Volume:0 Page:070206173308006-???
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venerol

Author:

Meiss F,Helmbold P,Meykadeh N,Gaber G,Marsch WCh,Fischer M

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1468-3083.2006.02026.x/fullpdf

Reference10 articles.

1. The immunological and clinical spectrum of delayed drug-induced exanthems

2. Acute generalized exanthematous pustulosis (AGEP) - A clinical reaction pattern

3. Acute generalized exanthematous pustulosis mimicking toxic epidermal necrolysis

4. Acute Generalized Exanthematous Pustulosis Resembling Toxic Epidermal Necrolysis Caused by Famotidine

5. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics, treatment and outcome of clindamycin induced acute generalized exanthematous pustulosis;Archives of Dermatological Research;2024-08-24

2. Severe cutaneous adverse reactions;Nature Reviews Disease Primers;2024-04-25

3. Determine and remove the drug trigger, usually antibiotics, that causes acute generalised exanthematous pustulosis;Drugs & Therapy Perspectives;2024-04

4. Hydroxychloroquine‐induced acute generalized exanthematous pustulosis (AGEP) treated with secukinumab;Journal of the European Academy of Dermatology and Venereology;2024-02-24

5. A retrospective analysis of mortality risk and immunosuppressive therapy for Stevens-Johnson Syndrome and toxic epidermal necrolysis syndrome using the TriNetX research network;Burns;2024-02